Adalvo is delighted to announce DCP approval of its Azacitidine tablets.
This milestone brings the company closer to expanding access to oral maintenance therapy for patients with acute myeloid leukaemia (AML).
Based on the reference brand, Onureg, oral Azacitidine is indicated as a maintenance therapy for patients who have achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi).
Taken once daily in tablet form, Azacitidine has demonstrated clinically meaningful improvements in survival and remission duration.
According to the 2021 Global Burden of Disease report, AML diagnoses increased by 82.8% between 1990 and 2021, largely driven by ageing populations. As demographics continue to shift globally, demand for effective AML maintenance therapies is expected to rise.
The addition of Azacitidine further strengthens Adalvo’s oncology portfolio, which is underpinned by technical expertise, regulatory clarity and a focus on partner-ready assets aligned with global market access and medical value.
To discuss licencing opportunities, or to see Adalvo’s complete oncology portfolio, contact one of the team today.